CSL Limited is a biotherapeutics company that develops and delivers biotherapies. The Company's principal activities are research, development, manufacture, marketing and distribution of biopharmaceutical and allied products. Its segments include CSL Behring, Seqirus and CSL Intellectual Property. The CSL Behring segment manufactures, markets and develops plasma therapies (plasma products and recombinants). The Seqirus segment manufactures and distributes non-plasma biotherapeutic products. Seqirus manufactures, sells and distributes a range of vaccines, antivenoms and other pharmaceutical products in Australia and New Zealand. It also manufactures and markets in vitro diagnostic products through Seqirus immunohematology. The CSL Intellectual Property segment is engaged in licensing of intellectual property generated by the Company to unrelated third parties. The Company has facilities in Australia, Germany, Switzerland, the United Kingdom and the United States.
Industry, Sector and Symbol:
- Sector: N/A
- Industry: N/A
- Sub-Industry: N/A
- Symbol: ASX:CSL
- CUSIP: N/A
- Web: www.csl.com.au/
Average Prices:- 50 Day Moving Avg: A$135.23
- 200 Day Moving Avg: A$124.94
P/E:- Trailing P/E Ratio: 43.51
- P/E Growth: 2.09
Dividend:
Profitability:- Net Margins: 21.89%
- Return on Equity: 58.70%
- Return on Assets: 20.48%
Frequently Asked Questions for CSL Limited (ASX:CSL)
What is CSL Limited's stock symbol?
CSL Limited trades on the ASX under the ticker symbol "CSL."
Who are some of CSL Limited's key competitors?
Some companies that are related to CSL Limited include Adelaide Brighton (ABC), AGL Energy Ltd (AGK), AGL Energy Ltd (AGL), Alacer Gold Corp - CDI (AQG), ALS Ltd (ALQ), Alumina Limited (AWC), Amcor Limited (AMC), AMP Limited (AMP), Ansell Limited (ANN), APA Group (APA), Aquarius Platinum Limited (AQP), Ardent Leisure Group (AAD), Aristocrat Leisure Limited (ALL), Arrium Ltd (ARI), Asciano Ltd (AIO), ASX Ltd (ASX), Atlas Iron Limited (AGO) and Augend Ltd (TTN).
Who are CSL Limited's key executives?
CSL Limited's management team includes the folowing people:
- Paul Perreault, Chief Executive Officer, Managing Director, Executive Director
- David Mark Lamont, Chief Financial Officer
- Gordon Naylor, President - Seqirus
- Greg Boss, Executive Vice President, Legal and CSL Group General Counsel
- Karen Etchberger, Executive Vice President - Quality and Business Services
- Bob Repella, Executive Vice President - Global Commercial Operations
- Val Romberg, Executive Vice President of Manufacturing and Planning
- Alan J. Wills, Senior Vice President - Strategy and Business Development
- Andrew Cuthbertson, Chief Scientific Officer, R&D Director
- Laurie Cowan, Senior Vice President - Human Resources
MarketBeat Community Rating for CSL Limited (ASX CSL)MarketBeat's community ratings are surveys of what our community members think about CSL Limited and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for CSL Limited (ASX:CSL) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | No ratings tracked in the last 12 months. |
| Consensus Rating: | N/A (Score: NaN) |
| Consensus Price Target: | N/A |
Analysts' Ratings History for CSL Limited (ASX:CSL)
Show:
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History for CSL Limited (ASX:CSL)
No earnings announcements for this company have been tracked by MarketBeat.com
Earnings Estimates for CSL Limited (ASX:CSL)No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for CSL Limited (ASX:CSL)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for CSL Limited (ASX:CSL)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for CSL Limited (ASX:CSL)
Latest Headlines for CSL Limited (ASX:CSL)
| Source: |
|
| Date | Headline |
|---|
 | 3 Things In Biotech You Should Learn Today: July 22, 2017
seekingalpha.com - July 23 at 5:14 PM |
 | CSL Behring Receives Orphan-Drug Exclusivity for HAEGARDA® (C1 Esterase Inhibitor Subcutaneous [Human]) - PR Newswire (press release)
www.prnewswire.com - July 22 at 5:21 AM |
 | CSL Behring Receives Orphan-Drug Exclusivity for HAEGARDA® (C1 Esterase Inhibitor Subcutaneous )
finance.yahoo.com - July 21 at 7:09 PM |
| Vaccines and Influenza Drugs Market to Grow 10.24% CAGR by ... - PR Newswire (press release)
www.prnewswire.com - July 20 at 7:32 PM |
| Seqirus Begins Shipping 2017-2018 Influenza Vaccines to the U.S. Market
finance.yahoo.com - July 20 at 7:32 PM |
| FDA Accepts CSL Behring's Supplemental Biologics License ... - PR Newswire (press release)
www.prnewswire.com - July 19 at 11:48 PM |
| FDA Accepts CSL Behring's Supplemental Biologics License Application for Hizentra® Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Indication
finance.yahoo.com - July 19 at 6:45 PM |
 | Anti-Infective Vaccines Market at 8.42% CAGR by 2021 Analysis by Disease and Vaccine Type at New Research in ReportsnReports
www.bizjournals.com - July 19 at 12:09 AM |
 | 3 small-cap healthcare shares to watch
www.fool.com.au - July 19 at 12:09 AM |
| Stocks to take advantage of a soaring Australian dollar - Motley Fool Australia
www.fool.com.au - July 18 at 7:07 PM |
| CSL Limited: a standout investment idea for 2018 and beyond
www.fool.com.au - July 14 at 3:22 PM |
| ETFs with exposure to CSL Ltd. : July 14, 2017
finance.yahoo.com - July 14 at 3:22 PM |
 | A Cancer Breakthrough Near FDA Approval Has a Costly Side Effect
www.bloomberg.com - July 13 at 4:22 AM |
 | BRIEF-CSL says new data demonstrate prophylactic treatment with idelvion reduces bleed frequency
www.reuters.com - July 13 at 4:22 AM |
| Australian dollar continues to strengthen: Two ways to profit - Motley Fool Australia
www.fool.com.au - July 12 at 11:22 PM |
| Is CSL Limited back in the buy zone? - Motley Fool Australia
www.fool.com.au - July 12 at 11:22 PM |
| New Data Demonstrate Prophylactic Treatment with IDELVION® Reduces Bleed Frequency and Has Potential to ... - PR Newswire (press release)
www.prnewswire.com - July 12 at 6:19 PM |
| New Data Demonstrate Prophylactic Treatment with IDELVION® Reduces Bleed Frequency and Has Potential to Positively Impact Patients with Haemophilia B
finance.yahoo.com - July 12 at 6:19 PM |
| 3 small-cap shares to watch in FY 2018 - Motley Fool Australia
www.fool.com.au - July 12 at 4:46 AM |
| 5 great ways to blow your huge 2017 bonus - Motley Fool Australia
www.fool.com.au - July 12 at 4:46 AM |
| CSL Behring Awards Researchers to Advance Immunoglobulin Therapy in Treating Neurological Disorders - PR Newswire (press release)
www.prnewswire.com - July 12 at 4:46 AM |
| CSL Behring Awards Researchers to Advance Immunoglobulin Therapy in Treating Neurological Disorders
finance.yahoo.com - July 11 at 6:43 PM |
| BRIEF-CSL Ltd responds to patent infringement complaint
www.reuters.com - July 10 at 5:34 PM |
| New Findings Show AFSTYLA® Provides Long-lasting Efficacy without Increased Product Consumption for Prophylactic and On-Demand Treatment of Haemophilia A
finance.yahoo.com - July 10 at 5:34 PM |
| New Data for Two Leading Haemophilia Medicines -- AFSTYLA® and IDELVION® -- to be Presented at the International Society on Thrombosis and Haemostasis Congress 2017
finance.yahoo.com - July 6 at 6:52 PM |
| CSL Ltd. breached its 50 day moving average in a Bearish Manner : CSL-AU : July 6, 2017
finance.yahoo.com - July 6 at 4:19 AM |
| Australia shares end marginally lower; NZ up
www.reuters.com - June 27 at 3:22 AM |
| FDA approves CSL Behring therapy for rare disease that can be administered at home
www.bizjournals.com - June 23 at 5:09 PM |
| FDA Approves HAEGARDA® (C1 Esterase Inhibitor Subcutaneous ), First and Only Subcutaneous Preventive Treatment for Hereditary Angioedema
finance.yahoo.com - June 23 at 5:09 PM |
| The CSL Limited share price climbs higher on FDA approval news - Motley Fool Australia
www.fool.com.au - June 23 at 2:54 AM |
| What is The Motley Fool Australia's Extreme Opportunities investing service? - Motley Fool Australia
www.fool.com.au - June 22 at 9:53 PM |
| Seqirus Announces Next Major Advancement in Cell-Based Influenza Vaccine Technology
finance.yahoo.com - June 21 at 5:50 PM |
| Week In Review: IHH Building $1 Billion Of China Hospitals; Seeks Deals For More - Seeking Alpha
seekingalpha.com - June 19 at 2:02 PM |
| ETFs with exposure to CSL Ltd. : June 15, 2017
finance.yahoo.com - June 15 at 6:26 PM |
| CSL Limited taps new all-time high at share price of $142
www.fool.com.au - June 14 at 10:29 PM |
| CSL Limited share price bounces even higher - Motley Fool Australia
www.fool.com.au - June 14 at 2:10 AM |
| CSL (CMXHF) Acquires Wuhan Zhong Yuan Rui De Biological Products - Slideshow
seekingalpha.com - June 13 at 9:09 PM |
| CSL to acquire majority stake in Chinese plasma fractionator Wuhan Zhong Yuan Rui De Biologicals Products - PR Newswire (press release)
www.prnewswire.com - June 13 at 4:09 PM |
| CSL to acquire majority stake in Chinese plasma fractionator Wuhan Zhong Yuan Rui De Biologicals Products
finance.yahoo.com - June 13 at 12:26 PM |
| Here’s why I’m so excited about Fisher & Paykel Healthcare Corp Ltd
www.fool.com.au - June 12 at 5:32 PM |
| Why these 4 ASX shares stormed higher today | Motley Fool Australia - Motley Fool Australia
www.fool.com.au - June 9 at 7:22 AM |
| Australia shares flat, propped up by GDP data; NZ lower
www.reuters.com - June 7 at 4:34 PM |
| 2 healthcare shares to pounce on at a lower price | Motley Fool ... - Motley Fool Australia
www.fool.com.au - June 2 at 11:02 PM |
| CSL Ltd. – Value Analysis (ASX:CSL) : June 2, 2017
finance.yahoo.com - June 2 at 6:01 PM |
| Australia shares buoyed by defensives while Wesfarmers slides; NZ higher
www.reuters.com - June 1 at 2:37 AM |
| 3 traits I look for in the best ASX shares
www.fool.com.au - June 1 at 2:37 AM |
| CSL Ltd. breached its 50 day moving average in a Bearish Manner : CSL-AU : June 1, 2017
finance.yahoo.com - June 1 at 2:37 AM |
 | Global Hemophilia Therapeutics Market Outlook 2022 - Anticipated to Witness Moderate Growth - Research and Markets
www.finanznachrichten.de - May 30 at 11:51 AM |
| Influenza Vaccines and Drugs Market Growing at a CAGR of 10.24% During 2017 to 2022 Says a Report at ReportsnReports.com
www.bizjournals.com - May 26 at 5:05 PM |
| 3 growth ideas: Buy, Hold, or Sell? - Motley Fool Australia
www.fool.com.au - May 23 at 3:46 PM |
